tiprankstipranks
Trending News
More News >

Vicore Pharma Increases Shares and Votes Following Warrant Exercise

Story Highlights
Vicore Pharma Increases Shares and Votes Following Warrant Exercise

Don’t Miss TipRanks’ Half-Year Sale

Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an update.

Vicore Pharma Holding AB has announced an increase in its number of shares and votes due to the exercise of warrants in its incentive programs. This development reflects the company’s ongoing efforts to enhance its capital structure and potentially strengthen its market position as it continues to advance its drug candidates.

More about Vicore Pharma Holding AB

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a new class of drugs with disease-modifying potential for respiratory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). Their leading product, buloxibutid (C21), is an oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the FDA and is currently in a Phase 2b trial.

YTD Price Performance: -6.86%

Average Trading Volume: 370,352

Current Market Cap: SEK1.85B

Learn more about VICO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1